Uncategorized
VIDEO: TearScience technology aimed at both diagnosing and treating MGD
CHICAGO — At the Ophthalmology Innovation Summit here, TearScience president and CEO Joseph Boorady talks about first diagnosing meibomian gland dysfunction with the company's LipiScan technology, then treating dry eye symptoms caused by MGD with LipiFlow. He said that recent study results showed a "powerful" sustained effect of a single LipiFlow treatment on dry eye symptoms, lasting up to 1 year.